Sorrento Therapeutics

Sorrento Therapeutics

Sorrento Therapeutics was founded in 2006 by Dr. Henry Ji and has since grown into a publicly traded company on the Nasdaq under the ticker SRNE. The company's origins trace to antibody engineering, and it has expanded through acquisitions and internal development to build a portfolio of over 20 clinical-stage programs. Sorrento's strategy focuses on three therapeutic areas: oncology, intractable pain, and infectious disease, including COVID-19. The company employs multiple modalities — antibody-drug conjugates, bispecific antibodies, cell therapy (through its CAR-T subsidiary), and non-opioid pain management via its resiniferatoxin platform. Key pipeline assets include a PD-L1-targeting antibody and a non-opioid pain therapeutic. Facilities span San Diego, Princeton, Nashville, Wilton, Los Altos, Paris, and Singapore, reflecting a global R&D and manufacturing footprint. The company has formed strategic partnerships with major pharmaceutical distributors and contract manufacturers to scale production and distribution. Sorrento also operates several subsidiaries, including Scilex Pharmaceuticals for pain management, and has a diagnostics arm for COVID-19 testing. Recent activity includes advancing its lead pain candidate through Phase 3 trials and securing regulatory approvals for its COVID-19 test in multiple markets. A structural differentiator is Sorrento's vertically integrated model: it controls discovery, development, manufacturing, and commercialization across subsidiaries, rather than licensing out candidates early. This approach retains a larger share of potential revenue but also concentrates risk within a single corporate structure.